Temporary Inhibition of "Polo Like Kinase-1" Using the siRNA Technique in Triple-Negative Breast Cancer Cells To Reduce the Expression of Mesenchymal Markers
ISEF · 2025 Cellular and Molecular Biology
Overview
In 2022, 2.3 million cases of breast cancer were diagnosed worldwide, with approximately 17% classified as triple-negative breast cancer (TNBC). TNBC is challenging to treat due to the absence of estrogen, progesterone, and HER2 receptors. Studies reveal ethnic disparities between non-Hispanic white (NHW) and Black women (NHB) using the MDA-MB-231 and MDA-MB-157 cell lines. Overexpression of Polo-Like Kinase-1 (PLK-1), a mitotic kinase in the G2 and M phases, promotes uncontrolled proliferation and treatment resistance. This study hypothesizes that inhibiting PLK-1 using the siRNA technique in TNBC will reduce the expression of epithelial-mesenchymal transition (EMT) markers: Vimentin, N-cadherin, ß-catenin, and E-cadherin. After 48 hours of siRNA transfection, RNA was converted into complementary DNA for RT-PCR analysis, and proteins were used for Western blotting. T-test results from RT-PCR showed a significant reduction in PLK-1 expression in both cell lines, with p-values of 0.009 in NHW-derived cells and 0.0152 in NHB-derived cells. Additionally, NHW-derived cells exhibited a decreasing trend in Vimentin, while NHB-derived cells showed an increasing trend in E-cadherin. Western blot results confirmed PLK-1 inhibition, with p-values of 0.0035 in MDA-MB-231 and 0.0009 in MDA-MB-157 cell lines. This resulted in an increasing trend of ß-catenin in MDA-MB-231, while in MDA-MB-157, there was a statistically significant reduction in N-cadherin (p-value of 0.0032) and a decreasing trend of Vimentin. These findings support siPLK-1 as a promising strategy for transitioning TNBC cells into a benign state, particularly in NHB women, who face the third-worst survival prognosis worldwide and showed the best response to this strategy.
Competition history
- ISEF 2025
Resources
Related projects
JSHS · 2025
Temporary inhibition of Polo Like Kinase-1 using the siRNA technique in triple-negative breast cancer cells to reduce the expression of mesenchymal markers
ISEF · 2016
Investigation of the Inhibitory Effect of Small Molecules on PLK1 Function in Triple Negative Breast Cancer
ISEF · 2014
Overcoming Resistance
ISEF · 2025
RNAi Therapy in Cancer Treatment II
ISEF · 2025
Single-Cell Analysis Based Identification of Unique Markers and Metastasis Mechanism in Triple-Negative Breast Cancer
ISEF · 2015
Targeting Hippo-Related Cell Polarity in Breast Cancer
ISEF · 2024
The Impact of Paclitaxel and Doxorubicin on APC Knockout Cells in Breast Cancer
ISEF · 2023
Cure of Breast Cancer-Year 6: Novel Approaches in the Therapy of Metastatic Breast Cancer Using Clinical Databases and 3D Organoid Model
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair